DSIP
A naturally occurring nine-amino-acid neuropeptide named for its association with delta-wave sleep, researched for decades for sleep architecture, stress modulation, and withdrawal support.
DSIP (Delta Sleep-Inducing Peptide) is a nonapeptide (Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu) first isolated in 1977 from the cerebral venous blood of sleeping rabbits by the Basel group of Schoenenberger and Monnier. Despite more than four decades of study, no receptor has ever been confirmed and its mechanism remains uncharacterized. Human clinical results have been inconsistent and it has never been approved anywhere, yet a persistent base of community responders and a real historical trial literature in sleep, stress, and addiction medicine keep research interest alive. It is a research compound with a favorable inherent safety profile but a narrow, unpredictable effect.
Class
Endogenous nonapeptide (9-amino-acid neuropeptide)
Half-life
~7-15 minutes IV plasma half-life; rapidly degraded by peptidases, though sleep-promoting effects are reported to last hours
Routes
Subcutaneous, Intranasal, Intramuscular, Intravenous (historical/research)
Category
Cognitive & Nootropic
Researched benefits
What it's studied for
Sleep architecture support
Named for delta-wave (deep) sleep, DSIP produced strong slow-wave EEG activity in the original rabbit experiments. Human effects are more modest and variable — some chronic-insomnia studies reported 5-15% increases in total sleep time and 10-20 minute reductions in sleep latency in responders, but response appears bimodal and inconsistent.
Stress and HPA-axis modulation
More consistent than the sleep data, DSIP reduces cortisol response to stress, blunts adrenergic/sympathetic activation, and produces a subjective sense of calm without sedation in animal and some human studies, possibly via inhibition of CRH release. This anti-stress effect may indirectly account for some reported sleep improvements.
Cortisol and ACTH regulation
DSIP influences hypothalamic-pituitary output, reducing stress hormones including ACTH and cortisol and interacting with central neuroendocrine pathways involved in recovery and circadian regulation.
Opioid tolerance and withdrawal support
DSIP potentiates endogenous opioid (enkephalin/endorphin) activity in some assays and has a genuine historical clinical application in alcohol and opioid withdrawal in Eastern European medicine, with a trial base more substantial than for most DSIP indications, though it is not a modern first-line treatment.
Pain modulation
DSIP shows analgesic activity in animal pain models and was studied in humans for chronic pain, likely via endogenous opioid potentiation, GABAergic modulation, and reduction of the affective dimension of pain. Clinical methodology was generally weak.
Non-habit-forming safety profile
Across decades of use DSIP shows no documented dependence, tolerance, withdrawal, or rebound insomnia, giving it a reputation as a mild, non-addictive alternative to benzodiazepines and z-drugs — though long-term data remain limited.
Mechanism
How it works
After more than four decades of research, DSIP's primary molecular target remains unknown. No specific receptor has been cloned, characterized, or reproducibly identified — a notable feature given that most peptide neuromodulators (oxytocin, vasopressin, CRH, ACTH) have well-defined G-protein coupled receptors. DSIP has been screened against classical opioid, GABA, serotonin, and dopamine receptors without clean binding at any single site, consistent with either a novel uncharacterized receptor or indirect modulation of multiple systems.
The pharmacological literature suggests DSIP likely acts through several indirect pathways: modulation of GABAergic transmission (increasing GABA release and potentiating GABA-A function, which may underlie sleep-promoting and anxiolytic effects), interaction with adrenergic systems (reducing noradrenergic outflow and locus coeruleus activity), opioid system modulation (potentiating endogenous enkephalin/endorphin tone), and hypothalamic-pituitary effects (influencing release of growth hormone, luteinizing hormone, and ACTH, though inconsistently across studies).
On sleep architecture, the original rabbit work showed strong delta-wave generation, but human studies have been modest and variable: total sleep time increases of 5-15%, sleep latency reductions of 10-20 minutes in responders, variable slow-wave sleep changes, and generally preserved REM sleep (unlike benzodiazepines). Response is bimodal — a subset of users respond clearly while others notice nothing, and no protocol adjustment is documented to convert a non-responder.
DSIP is a small hydrophilic peptide (848 Da) that undergoes rapid enzymatic degradation, with an extraordinarily short plasma half-life of roughly 7-15 minutes. Despite this, clinical effects often outlast plasma exposure, suggesting metabolite activity, rapid CNS penetration during the brief plasma window, or downstream cascade effects. Intranasal delivery may improve CNS access via the olfactory pathway, one rationale for the popularity of nasal spray formulations.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
DSIP ships as a lyophilized white powder, typically in 5 mg vials. Reconstitute with sterile bacteriostatic water — a common approach is 5 mg in 2 mL BAC water, yielding 2,500 mcg/mL (1 unit on an insulin syringe = 25 mcg; 100 mcg = 4 units, 200 mcg = 8 units, 300 mcg = 12 units). A 5 mL reconstitution yields 1,000 mcg/mL (1 unit = 10 mcg) for more forgiving draws. Add water gently down the vial wall, swirl (do not shake), store reconstituted solution refrigerated at 2-8°C for up to ~30 days. For intranasal use, reconstitute with sterile saline rather than BAC water to avoid benzyl-alcohol nasal irritation.
Beginner
- Dose
- 100 mcg (Week 1), titrating to 150 mcg (Week 2), then 200 mcg (Week 3+) if tolerated
- Frequency
- Once nightly
- Timing
- 30-60 minutes before intended sleep
- Duration
- Trial for 2-4 weeks to establish responder status
- Route
- Subcutaneous (or intranasal ~200 mcg = 1 spray per nostril)
Single-agent trial to identify whether you are a responder. Track baseline sleep latency, total sleep time, and subjective quality for 1-2 weeks first. Start low; more DSIP does not produce more sleep, only more grogginess.
Standard sleep support
- Dose
- 200 mcg (SC) or 250-400 mcg (intranasal)
- Frequency
- Nightly or 5 nights per week
- Timing
- 30-45 minutes before bed
- Duration
- Ongoing intermittent; commonly 5 nights on, 2 off
- Route
- Subcutaneous or intranasal
Maintenance dose for most confirmed responders. Consistent nightly timing appears most effective. Pair with optimized sleep hygiene rather than replacing it.
Stronger-effect / advanced
- Dose
- 200-300 mcg (do not exceed 300 mcg)
- Frequency
- Nightly with periodic breaks
- Timing
- 60 minutes before bed
- Duration
- 8-12 week cycles with 2-4 week breaks; or intermittent
- Route
- Subcutaneous
Often part of an evening peptide stack (e.g. with CJC-1295/Ipamorelin or Tesamorelin for GH-mediated recovery). Doses above 300 mcg do not improve efficacy and increase morning grogginess and vivid dreams.
Withdrawal / pain adjunct
- Dose
- 200-300 mcg
- Frequency
- 2-3x daily (withdrawal) or daily (chronic pain)
- Timing
- Per clinical context
- Duration
- Acute (withdrawal) or physician-supervised
- Route
- Subcutaneous
Historical clinical applications; medical supervision required and not recommended for self-directed use.
- DSIP is dosed in micrograms (mcg), not milligrams — confusing mcg and mg leads to dramatic overdosing. 100 mcg is NOT 100 units on a syringe.
- No FDA-approved human dosing protocol exists; all regimens are community/research-derived. Early human studies from the 1970s-80s used IV infusion at nanogram-to-microgram per kg ranges and are dated and unreplicated.
- Response is bimodal — roughly 30-40% clear responders, 30-40% partial, 20-40% non-responders. If no benefit appears after 4 weeks at 200 mcg, you are likely a non-responder.
- No taper is required on discontinuation; there is no withdrawal syndrome or rebound insomnia, and it can be resumed at the previous effective dose.
- Optimize sleep hygiene and rule out sleep apnea, RLS, thyroid dysfunction, and untreated depression/anxiety before relying on DSIP — no peptide compensates for these.
- Intermittent use (5 on/2 off, or 3-4 nights weekly) helps distinguish pharmacological from placebo effect and avoids theoretical tolerance.
Evidence
Research & clinical studies (1)
The delta-sleep inducing peptide (DSIP) increases duration of sleep in rats
Administration of DSIP increased total sleep duration in rats, providing early evidence for a role in sleep-wake regulation, though subsequent research has yielded inconsistent results across species and conditions.
PMID 530466Combinations
Stacking & blends
DSIP + Selank: Sleep & Anxiety Relief
Improve sleep quality while reducing the daytime anxiety and stress load that prevents sleep onset
DSIP is proposed to increase slow-wave delta sleep and normalize circadian sleep patterns by modulating hypothalamic sleep-wake centers, while Selank provides daytime anxiolytic and mood-stabilizing effects. The combination targets both the quality of sleep and the psychological barriers to achieving it. Time-separate Selank to the morning/day and DSIP to the evening.
Evening GH-recovery stack
Enhance overnight recovery via a growth-hormone pulse during deep sleep
DSIP supports the sleep architecture that makes the nocturnal GH/IGF-1 pulse possible, while CJC-1295 + Ipamorelin (often combined ~100/200 mcg in a single bedtime syringe) drive the GH release. Generally considered safe and potentially synergistic.
DSIP + Tesamorelin
Sleep architecture plus more robust GH/IGF-1 and visceral-fat effects
An alternative single-peptide GH approach — Tesamorelin 1 mg SC at bedtime replaces CJC/Ipamorelin for a stronger GH effect, with DSIP 200-300 mcg for sleep depth.
DSIP + Epitalon (circadian layer)
Circadian and pineal support alongside nightly sleep architecture
Epitalon cycles (5-10 mg SC daily for 10-20 days each quarter) may support pineal function and circadian-rhythm restoration in aging users, complementing DSIP's per-night sleep effect.
DSIP + Melatonin (low dose)
Combine circadian timing with sleep depth
Low-dose melatonin (0.3-0.5 mg) anchors circadian timing while DSIP modulates sleep architecture and stress — a synergistic pairing. Use genuine low-dose melatonin, since high doses cause vivid dreams and morning hangover and can reduce benefit.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy (insufficient safety data)
- Lactation (insufficient safety data)
- Known allergy or hypersensitivity to DSIP
- Untreated moderate-severe obstructive sleep apnea (treat the apnea first)
- Severe respiratory disease with hypercapnia
- Acute intoxication with sedative substances (additive CNS depression)
- Pediatric and adolescent use
- Concurrent benzodiazepines, z-drugs, opioids, or alcohol (additive sedation — avoid or reduce doses)
DSIP has one of the cleanest safety profiles in the peptide space, with no reported dependence, tolerance, withdrawal, cognitive impairment, or respiratory depression, but long-term human safety data are genuinely limited (most trials ran weeks, not years). Verify next-day alertness before driving or operating machinery. Formal drug-interaction studies are lacking; combine additive sedatives only thoughtfully. Discontinue and seek evaluation for persistent morning sedation, worsening sleep, new mood changes, disruptive vivid dreams, or any allergic-type reaction.
FAQ
DSIP — common questions
Does DSIP actually work for sleep?
It produces modest, inconsistent sleep benefits in humans — nothing like the dramatic sedation the name 'delta sleep-inducing peptide' implies. Roughly 30-40% of users notice clear improvement, 30-40% partial, and 20-40% no effect. The clinical evidence supports small improvements in sleep latency and subjective quality, not benzodiazepine-level sleep induction. As a mild, non-habit-forming assist alongside good sleep hygiene it can be reasonable.
What is the typical starting dose?
For sleep support, 100 mcg subcutaneously 30-60 minutes before bed is a conservative start, titrating to 200 mcg as maintenance. Doses above 300 mcg do not produce proportionally more benefit and increase morning grogginess and vivid dreams. Intranasal products typically deliver 100-200 mcg per dose.
Is DSIP FDA-approved?
No. DSIP has never been FDA-approved for any indication despite 40+ years of study; it never completed the large Phase 3 trials modern approval requires. It circulates only as a 'research use only' compound. As of April 22, 2026 it was removed from the FDA's Category 2 bulk substances list and is scheduled for PCAC review in July 2026.
How is DSIP administered?
Most commonly subcutaneous injection (precise dosing, reliable absorption) or intranasal spray (needle-free, bypasses first-pass metabolism, but dose consistency can vary). Intravenous was used historically in research; oral capsules are essentially ineffective due to GI degradation and sublingual absorption is poor.
Why does DSIP have such a short half-life but effects that last hours?
DSIP is a small peptide rapidly degraded by peptidases, giving a plasma half-life of roughly 7-15 minutes. Effects outlasting exposure are attributed to active metabolites, rapid CNS penetration during the brief plasma window, or downstream cascade effects that continue beyond the peptide's presence.
Can DSIP be used nightly indefinitely?
Probably safe based on limited data — it shows no known dependence, tolerance, or withdrawal — but long-term data are limited and it is not ideal practice. Prudent use is intermittent (5 nights on/2 off, or 3-4 nights weekly) with periodic 2-4 week breaks every few months.
How does DSIP compare to melatonin?
Different mechanisms. Melatonin is a circadian signaling hormone (best at low 0.3-0.5 mg doses for timing), while DSIP modulates sleep architecture and stress response through an uncharacterized mechanism. Low-dose melatonin for timing plus DSIP for depth can be synergistic; high-dose melatonin alone is often less effective.
What are the main side effects?
Most common are next-morning grogginess at higher doses, vivid dreams, mild injection-site reactions, and mild nasal irritation for intranasal users. Uncommon: headache, dizziness, mild mood changes, rare paradoxical sleep disruption. Not reported: dependence, tolerance, withdrawal, or respiratory depression.
